Top-News

Xencor Aktie News

Aktie
WKN:  A1W96L ISIN:  US98401F1057 US-Symbol:  XNCR Branche:  Biotechnologie Land:  USA
14,40 €
+0,2 €
+1,41%
07:43:26 Uhr
Depot/Watchlist
Marktkapitalisierung *
905,20 Mio. €
Streubesitz
-
KGV
-7,23
Index-Zuordnung
-

Xencor News

09.12.25 - Businesswire
Xencor Announces Extension of U.S. Patent Term on Certain Xtend™ Antibodies
Xencor, Inc. (NASDAQ:XNCR), a clinical-​stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today ...
10.11.25 - Businesswire
Xencor to Participate at Upcoming Investor Conferences
Xencor, Inc. (NASDAQ:XNCR), a clinical-​stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today ...
05.11.25 - Businesswire
Xencor Reports Third Quarter 2025 Financial Results
Xencor, Inc. (NASDAQ:XNCR), a clinical-​stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported ...
24.10.25 - Businesswire
Xencor Presents Initial Data for XmAb819, a First-in-class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Clear Cell Renal Cell Carcinoma
Xencor, Inc. (NASDAQ:XNCR), a clinical-​stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today ...
21.10.25 - Businesswire
Xencor to Host Webcast and Conference Call to Discuss Initial Results from the Ongoing Phase 1 Dose-Escalation Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma
Xencor, Inc. (NASDAQ:XNCR), a clinical-​stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, will host a ...
17.10.25 - PR Newswire
Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation
Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation PR Newswire
17.10.25 - PR Newswire
Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation
Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation PR Newswire
14.10.25 - Businesswire
Xencor Announces Presentation of Initial Phase 1 Dose-Escalation Results of XmAb819 in Clear Cell Renal Cell Carcinoma at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Xencor, Inc. (NASDAQ:XNCR), a clinical-​stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today ...

Newssuche

Videos

newspaper
10:40 Uhr +0,47%
Technical Trading: Zucker Long zum Jahresende
Zucker Long Typ: Turbo Open End WKN: VP89SL Hebel: 5,88 Laufzeit: OpenEnd Einstieg: Market ... Mehr »